Research programme: peptide therapeutics - Intarcia Therapeutics
Alternative Names: GLP-1 DUROS®; Glucagon-like peptide-1 DUROS®; ITCA-880; ITCA-884Latest Information Update: 03 May 2016
At a glance
- Originator Intarcia Therapeutics
- Class
- Mechanism of Action Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 03 May 2016 Discontinued - Preclinical for Obesity in USA (SC)
- 03 May 2016 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (SC)
- 25 Feb 2011 No development reported - Preclinical for Type-2 diabetes mellitus in USA (SC)